5-Methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo? A phase II study in patients with advanced colon cancer

Camillo Porta, Mauro Moroni, Oscar Epis, Giuseppe Nastasi

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to test the hypothesis that 5-methyltetrahydrofolate (Me-THF), a source of reduced folates alternative to leucovorin, could effectively modulate 5-fluorouracil's (5-FU) cytotoxic activity in patients with advanced colon cancer. A total of 23 patients were enrolled in a phase II trial; they received 5-FU as a 30-min infusion at a dose of 370 mg/m2 following a rapid i.v. push of 200 mg/m2 Me-THF, both drugs being given for 5 consecutive days. Cycles were repeated every 4 weeks until disease progression. No patient achieved a complete response. In all, 4 patients showed a partial response (17.4%), 7 developed stable disease (30.4%), and the remaining 12 (52.2%) progressed. Toxicity was acceptable and never exceeded WHO grade III intensity. According to our experience, the MeTHF/5-FU combination does not appear to be an effective treatment for advanced colon cancer. Despite its low toxic profile, in our opinion its wider use should be discouraged.

Original languageEnglish
Pages (from-to)195-197
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume38
Issue number2
DOIs
Publication statusPublished - 1996

Keywords

  • 5-FU
  • 5-methyltetrahydrofolate
  • advanced disease
  • biologic modulation
  • colon cancer
  • phase II trial

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of '5-Methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo? A phase II study in patients with advanced colon cancer'. Together they form a unique fingerprint.

  • Cite this